¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid
Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.
Boost Now or Wait? Many Wonder How Best to Ride Out Covid’s Next Wave
As the country faces a rise in new infections driven by the omicron BA.5 subvariant of the coronavirus, about 70% of people 50 and older who got a first covid-19 booster shot haven’t received the recommended second one, according to the Centers for Disease Control and Prevention. Many undervaccinated Americans have lost interest, and others aren’t sure whether to get boosted again now or wait for vaccines reformulated to target newer strains of the virus.
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
Cómo Pfizer le ganó a la pandemia, alcanzando influencia y ganancias descomunales
Su éxito en el desarrollo de medicamentos contra covid le ha dado a la farmacéutica un peso inusual en la determinación de la política de salud de Estados Unidos. Algo que preocupa a expertos.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
Por qué adultos mayores de minorías no reciben la vacuna de alta dosis contra la gripe
Esta vacuna reforzada contra la influenza, podría ser más efectiva contra el virus, pero es más costosa. Y no suele estar disponible para las poblaciones más vulnerables.
Why Black and Hispanic Seniors Are Left With a Less Powerful Flu Vaccine
Federal health officials haven’t taken a clear position on whether a high-dose influenza vaccine — on the market since 2010 — is the best choice for people 65 and older. Many in that group already opt for the costlier enhanced shot. Those who get the standard vaccine are disproportionately members of ethnic and racial minorities.
Pfizer CEO Pushes Yearly Shots for Covid. Not So Fast, Experts Say.
A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
How LA, Calling the Shots on School Vaccine Mandates, Can Lead the Way on Covid Rules
In the middle of a measles outbreak in 1977, the Los Angeles school system required students to be inoculated or stay out of class. Other school systems followed the practice. Will it work again now that the county is insisting that teens have their shots against covid?
Stranded by the Pandemic, He Had Only Travel Insurance. It Left Him With a $38,000 Bill.
Although it’s possible to buy travel insurance that provides some health coverage, the devil is in the fine print. Obama-era laws that prevent refusal of payment for preexisting conditions don’t apply to travel insurance.
Ser inmune a covid por haberlo tenido o estar vacunado, ¿es lo mismo?
Hay pruebas de que contraer SARS-CoV-2 genera inmunidad. Pero muchos científicos creen que no son contundentes.
Covid Immunity Through Infection or Vaccination: Are They Equal?
As scientists argue whether a previous bout of covid offers the same amount of protection as vaccinations, people turn to the courts to decide.
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies weren’t yet convinced. A meeting Friday will determine what happens next. Here’s the story from behind the scenes.
Federal Vaccine Program Hasn’t Helped Those Whose Lives Were Altered by Covid Shot
A national vaccine court has paid out billions to families who could prove their kids were injured by vaccines. But there’s only a skeletal program for the rare victims of covid vaccination, raising concerns as the pressure for mandated shots grows.
Not All Experts Are Ready to Vaccinate Kids Against Covid
Rare reports of minor heart damage have convinced some scientists that further study is needed before racing to extend covid shots to more children.
Analysis: Mounting Pressure on China About Covid ‘Lab Leak’ Could Backfire
Where the coronavirus originated remains a mystery and the Chinese are bucking demands to let investigators see more.
La idea de que el virus que causa covid escapó de un laboratorio chino, una teoría que en su momento se consideró conspirativa, está cobrando fuerza. Al mismo tiempo, peligra la reputación de renombrados científicos, al igual que su seguridad personal.
